Company Overview
KalVista Pharmaceuticals, Inc. operates within the healthcare sector as a biotechnology entity dedicated to the discovery, development, and commercialization of drug therapies, specifically focusing on inhibitors for diseases with unmet medical needs. Its primary product candidate, EKTERLY, is identified as a small molecule plasma kallikrein inhibitor designed to target specific disease pathways. The company maintains a workforce of 270 employees, supporting its operational scope in biopharmaceutical research and development. With a market capitalization of $831.99M and reported annual revenue of $1.43M, the company's valuation reflects the high-risk, high-potential nature typical of early-stage biotechnology firms. The significant disparity between its substantial market cap and minimal revenue indicates that the market price is driven primarily by the potential value of its pipeline assets and intellectual property rather than current operational cash flows.
Financial Health
The company reported a revenue of $1.43M over the trailing twelve months, yet posted a net income of $-203,096,992 and an EBITDA of $-201,820,000. The vast gap between the low revenue figure and the massive net loss reveals a cost structure dominated by high R&D expenditures and operational overheads common in drug development phases. Free cash flow stands at $-100,205,000, indicating that the company is burning through cash reserves to fund its growth initiatives and scientific programs. Gross margin is recorded at 0.0%, operating margin at -336.3%, and profit margin at 0.0%, which collectively signify that the company has not yet achieved commercial profitability from its product sales. On the balance sheet, the company holds $309.16M in cash against $282.58M in debt, resulting in a debt-to-equity ratio of 1662.33. Despite the elevated debt-to-equity figure, the current ratio of 5.37 suggests a robust short-term liquidity position capable of covering liabilities several times over. Return on Equity is -190.2% and Return on Assets is -61.0%, metrics that reflect the dilutive effect of accumulated losses on the equity base and the asset base respectively.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the absence of positive earnings, while the Forward P/E is -11.12, illustrating that the market is pricing the stock based on future anticipated earnings rather than historical performance. The price-to-book ratio is 48.99, indicating that the stock trades at a significant premium relative to its book value, a common characteristic for biotech companies where assets are heavily weighted toward intangible research potential. The price-to-sales ratio is 583.44 and the EV/EBITDA is -3.99, suggesting that valuation multiples are extremely sensitive to the company's ability to transition from a cash-burning stage to a revenue-generating stage. The stock has a 52-week high of $19.00 and a 52-week low of $9.23, with the current market price trading somewhere within this defined volatility range. The beta value of -0.29 is anomalous for an equity security, suggesting an inverse correlation with the broader market or significant statistical irregularities in the price data provided.
Growth & Income
Revenue growth and earnings growth are both marked as N/A, indicating that the company is not currently in a phase of scaling revenue or generating positive earnings growth comparable to mature industry peers. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Instead, the firm retains all earnings, or rather, its remaining cash reserves, to reinvest into the development of its drug therapies and to sustain its operational costs. The overall growth and income profile is characterized by a complete reliance on future product commercialization to generate returns, with no current contribution to shareholder income through dividends or earnings growth.